Form 4: JNJ Director Nadja West Receives Deferred Share Units

Johnson & Johnson Director Nadja West was granted 975 deferred share units as part of the company's director compensation plan.

Summary

• Director Nadja West acquired 975 deferred share units (DSUs) on April 23, 2026.
• The DSUs were granted under the Johnson & Johnson Amended and Restated Deferred Fee Plan for Directors.
• These units are to be settled in cash upon the termination of the reporting person's directorship.
• The total number of DSUs held by the reporting person following this transaction is 7,730.0491.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation with no impact on company operations or financial health.

Positives

• The transaction reflects standard director compensation practices, aligning the interests of the board member with the company's long-term performance.

Negatives

• None.

Risks

• The value of the deferred share units is tied to the future market performance of Johnson & Johnson common stock.

Future Outlook

The DSUs will be settled in cash upon the termination of the reporting person's directorship, with the value determined by the fair market value of common stock at that time.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation, consistent with standard corporate governance practices for large-cap pharmaceutical companies.

Comparison to Industry Standards

• The use of deferred share units for director compensation is a standard practice among S&P 500 companies to ensure board members maintain a long-term stake in company performance.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard component of director compensation.

Next Steps

• No further action required; the filing is a record of a completed transaction.

Key Dates

Keywords

Johnson & Johnson, JNJ, Director Compensation, Deferred Share Units, Insider Transaction, SEC Form 4